Previous studies indicated that suppression of HDAC2 activity by small-molecule therapeutics might display beneficial effects in the improvement of neurocognitive function [42,43] and the amelioration of AD pathologies [44], such as the removal of amyloid plaque burden [45] and the attenuation of Tau pathologies [46]. This evidence concerns the gene MAPT and Alzheimer disease.